Alife’s AI Technology Now Available on Hamilton Thorne Laser Systems
The partnership between Hamilton Thorne, Inc. & Alife Health aims to expand access to cutting-edge AI technology to support clinical...
Pharmaceutical
Coronado Research announce engagement of Rob Nichols to support the growth of their Clinical Technology Practice
LONDON, Oct. 3, 2024 /PRNewswire/ -- Today, Coronado Research announced the engagement of Rob Nichols to support the build-out of...
180 Life Sciences Corp. – Corporate Updates
Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA /...
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology LAS VEGAS,...
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
Robert Edwards, MD, UPMC, Magee-Womens Hospital Robert Edwards, MD, UPMC, Magee-Womens Hospital Thomas Equels, CEO of AIM ImmunoTech Inc Thomas...
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024The collaboration...
NMS Capital Portfolio Company Surplus Solutions Expands Internationally; Announces Partnership with FAMECO Group ApS
NEW YORK and STRASBOURG, France, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Surplus Solutions LLC (“Surplus Solutions”), a portfolio company of...
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement...
Recent clinical data confirms significantly improved predictive power of Evaxion’s AI-Immunology™ platform
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates...
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical...
Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024
New products complement an already extensive range of products enabling fundamental advancements in neuroscience researchHOLLISTON, Mass., Oct. 03, 2024 (GLOBE...
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting...
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Nusano Adds to Executive Leadership Team in Advance of 2025 Commercialization
VALENCIA, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Nusano, Inc., a physics company transforming the production of medical radioisotopes, today...
ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth
LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and...
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell...
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts Ongoing...
Neural Therapeutics Inc. Announces Letter of Intent with Leading German Hemp-Based Product Retailer “Hanf.com”
Toronto, Ontario--(Newsfile Corp. - October 3, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company...